# Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

> **NCT00073125** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 103 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** ABT-510/Thrombospondin-1 mimetic

## Key facts

- **NCT ID:** NCT00073125
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2007-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073125, "Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00073125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*